Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases

DOI PDF 3 Citations
  • Yuping Lai
    Shanghai Key Laboratory of Regulatory Biology, School of Life Science, East China Normal University 1 , No.500 Minhang Dongchuan Road, Shanghai 200241 , China
  • Chen Dong
    Institute for Immunology, Tsinghua University 2 , Medical Research Building D330, No.30 Haidian Shuangqing Road, Beijing 100084 , China

Abstract

<jats:title>Abstract</jats:title><jats:p>Inflammatory cytokines are key regulators of immune responses. Persistent and excessive production of inflammatory cytokines underscores the development of autoimmune diseases. Therefore, neutralizing inflammatory cytokines or antagonizing their receptor function is considered as a useful therapeutic strategy to treat autoimmune diseases. To achieve the success of such a strategy, understanding of the complex actions of these cytokines and cytokine networks is required. In this review we focus on four inflammatory cytokines—tumor necrosis factor α (TNFα), interleukin-6 (IL-6), IL-23 and IL-17—and dissect how the dysregulation of these cytokines regulates autoimmune diseases. On the basis of pre-clinical and clinical data, we specifically discuss the therapeutic rationale for targeting these cytokines and describe the potential adverse effects.</jats:p>

Journal

Citations (3)*help

See more

Details 詳細情報について

Report a problem

Back to top